October 15, 2023

SAN DIEGO, October 15, 2023 -- Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has earned a Deals of Distinction award from the Licensing Executives Society (LES) for its Collaboration, Option and License Agreement with Astellas announced earlier in 2023. The Deals of Distinction awards are given each year to recognize major licensing transactions that exemplify best practices and creativity to achieve strategic business objectives. The award recognizes worthy licensing deals that promote creative and innovative solutions to business issues involving contracts. More information about this prestigious award can be found on the LES webpage: https://members.lesusacanada.org/page/dda

About Cullgen Inc.

Cullgen is a privately held clinical-stage biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. The company applies its proprietary uSMITE™ (ubiquitin-mediated, small molecule - induced target elimination) platform to expand the drug design paradigm beyond functional site inhibition, enabling the targeting of historically “undruggable” proteins for selective destruction. Leveraging years of work by its founders on the proteasome system and key discoveries regarding its functionality, Cullgen has successfully generated multiple highly potent, selective, and bioavailable targeted protein degrader compounds that utilize proprietary novel E3 ligands. For more information, visit www.cullgen.com.

Contacts

Cullgen Inc.

Seth Goldblum, SVP - Corporate Development

inquiries@cullgen.com